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ABSTRACT
Objective Dysregulated immune responses are the 
cause of IBDs. Studies in mice and humans suggest a 
central role of interleukin (IL)-23- producing mononuclear 
phagocytes in disease pathogenesis. Mechanistic 
insights into the regulation of IL-23 are prerequisite for 
selective IL-23 targeting therapies as part of personalised 
medicine.
Design We performed transcriptomic analysis to 
investigate IL-23 expression in human mononuclear 
phagocytes and peripheral blood mononuclear cells. We 
investigated the regulation of IL-23 expression and used 
single- cell RNA sequencing to derive a transcriptomic 
signature of hyperinflammatory monocytes. Using gene 
network correlation analysis, we deconvolved this 
signature into components associated with homeostasis 
and inflammation in patient biopsy samples.
Results We characterised monocyte subsets of healthy 
individuals and patients with IBD that express IL-23. 
We identified autosensing and paracrine sensing of 
IL-1α/IL-1β and IL-10 as key cytokines that control 
IL-23- producing monocytes. Whereas Mendelian genetic 
defects in IL-10 receptor signalling induced IL-23 
secretion after lipopolysaccharide stimulation, whole 
bacteria exposure induced IL-23 production in controls 
via acquired IL-10 signalling resistance. We found a 
transcriptional signature of IL-23- producing inflammatory 
monocytes that predicted both disease and resistance 
to antitumour necrosis factor (TNF) therapy and 
differentiated that from an IL-23- associated lymphocyte 
differentiation signature that was present in homeostasis 
and in disease.
Conclusion Our work identifies IL-10 and IL-1 as 
critical regulators of monocyte IL-23 production. 
We differentiate homeostatic IL-23 production from 
hyperinflammation- associated IL-23 production in 
patients with severe ulcerating active Crohn’s disease 
and anti- TNF treatment non- responsiveness. Altogether, 
we identify subgroups of patients with IBD that might 
benefit from IL- 23p19 and/or IL-1α/IL-1β-targeting 
therapies upstream of IL-23.
INTRODUCTION
The pathogenesis of inflammatory bowel disease 
(IBD), which includes Crohn’s disease (CD) and 
Significance of this study
What is already known on this subject?
 ► IBD is a complex chronic inflammatory 
disease caused by the interaction of 
host and environmental factors in a 
genetically susceptible setting. Targeting the 
proinflammatory arm of the immune system 
such as by blocking tumour necrosis factor 
(TNF) signalling has proven therapeutically 
successful in subgroups of patients with IBD. 
Studies in both mice and humans indicate 
interleukin (IL)-23 as a key pathogenic 
proinflammatory factor in IBD. Early- stage 
clinical trials indicate that blocking IL-23 
can induce disease remission in patients 
with Crohn’s disease (CD) and ulcerative 
colitis (UC). As part of personalised medicine, 
mechanistic insights into the regulation of IL-23 
are prerequisite for selective IL-23 targeting 
therapies.
What are the new findings?
 ► We identify autocrine and paracrine sensing 
of IL-1α/IL-1β and IL-10 as key cytokines 
that control IL-23- producing monocytes. We 
determine a transcriptional signature of IL-
23- producing monocytes that predicted both 
disease and resistance to anti- TNF therapy 
and differentiate this hyperinflammation- 
associated IL-23 production in patients with 
severe ulcerating active CD from homeostatic 
intestinal IL-23 production. We show that 
exposure of monocytes to whole bacteria 
induced IL-23 production via acquired IL-10 
signalling resistance akin to IL-23 secretion by 
lipopolysaccharide- stimulated monocytes in 
Mendelian IL-10 signalling defects.
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ulcerative colitis (UC) and IBD unclassified (IBDu), is caused 
by dysregulated innate and adaptive immune responses that 
drive chronic relapsing tissue inflammation.1 Genetic studies 
suggest a complex polygenic inheritance driven by defective 
innate and adaptive immunity.1 2 Interleukin (IL)-23 signalling 
and T- helper (Th)1/Th17 immunity are significant mediators of 
intestinal inflammation as indicated by genetic variants in IL23R 
encoding the IL-23 receptor3 as well as RORC, STAT3, IRF5, 
IL1R1, IL6ST, IL12B, TYK2, IL21, JAK2, IFNG, SMAD3 and 
CCR6.4 5 Monocytes, macrophages and dendritic cells (DCs) 
produce IL-23 in response to bacteria- and fungi- derived micro-
bial stimuli and drive Th1 and Th17 differentiation in the patho-
genesis of intestinal inflammation.6–9 In addition to a role of 
pro- inflammatory and anti- inflammatory cytokine networks,10 
mouse models as well as human Mendelian disorders highlight 
the essential role of IL-10 signalling in controlling inflammatory 
cytokine responses. Therapeutic approaches that target the pro- 
inflammatory arm of the immune system by blocking cytokine 
signalling or by affecting intestinal cell migration are effective 
in subgroups of patients with IBD.8 Mice that lack IL- 23p19 are 
protected from developing colitis in innate as well as lympho-
cyte replete models of intestinal inflammation induced by IL-10 
signalling defects, bacterial colonisation or innate immune stim-
ulation via the anti- CD40.7 11 These results indicate that IL-10 
blockade unleashes an IL-23 mediated immune pathogenesis. 
Importantly, blockade of IL- 23p19 and IL- 12p40 showed thera-
peutic benefit for patients with CD and UC.12 13
To predict genetic susceptibility or disease course, individual loci 
and genetic risk scores14 15 as well as gene expression signatures 
or transcriptomic scores of peripheral CD8+ T cells,16 periph-
eral blood17 or intestinal tissue18 are revealing patient stratifica-
tion strategies in IBD. Membrane- bound tumour necrosis factor 
(TNF)19 and IL-6/oncostatin M (OSM) associated cytokines18 
predict anti- TNF non- response. However, transcriptional signa-
tures informed by IL-23 expression have not been described.
Personalised medicine targeting the IL-23 axis requires an 
understanding of the cellular sources, networks and regulation 
of IL-23. Here we investigate the regulation of IL-23, describe 
distinct monocyte subsets that express IL-23 and identify IL-1 
signalling as the key cytokine for the differentiation of IL-23- 
producing monocytes. We identify a hyperinflammatory signature 
of IL-23- producing monocytes in intestinal tissue transcriptomes 
of patients with IBD and find an additional signature of IL-23 that 
is associated with lymphocyte cell differentiation in healthy tissue.
METHODS
Detailed methods are outlined in the online supplemental materials.
RESULTS
IL-10 signalling blockade facilitates IL-23 production by a 
subset of peripheral blood monocytes
We investigated the regulation of IL23A expression by subjecting 
peripheral blood mononuclear cells (PBMC) from 41 patients 
with IBD (online supplemental figure 1A and online supple-
mental table 1) to IBD- relevant stimuli that target different 
aspects of innate and adaptive immune cell responses. Lipopoly-
saccharide (LPS), muramyl- dipeptide (MDP), T- cell receptor and 
costimulation (αCD3/αCD28 coated beads) and IL-10 signalling 
blockade were used alone or in combination based on the concept 
that innate pathogen recognition receptor responses in partic-
ular, NOD214and TLR4,20 T- cell responses and IL-10 signalling 
defects are implicated by multiple genetic IBD susceptibility loci 
and Mendelian forms of IBD.21 We performed microarray gene 
expression analysis of all conditions at 16 hours following stim-
ulation in the presence or absence of IL-10 receptor (IL- 10R) 
blocking antibodies. We identified stimulus- specific and shared 
gene expression signatures (online supplemental figure 1B,C and 
online supplemental table 2). LPS, L18MDP and αCD3/αCD28 
coated beads induced 319, 187 and 312 genes, respectively, 
out of which 109, 19 and 175 were condition- specific genes 
(Benjamini-­Hochberg­ (BH)-­adjusted­ p<0.05,­ fc≥1.5;­ online­
supplemental figure 1B). Changes in IL23A expression were 
moderate under these conditions (online supplemental figure 
1C). We next investigated the role of IL-10 signalling during 
LPS, L18MDP and αCD3/αCD28 stimulation. In total, 36 genes 
were upregulated and 29 genes were downregulated by IL-10 
blockade, with most of the changes being found during LPS 
stimulation­(fc>1.5,­BH-­adjusted­p<0.05;­online­supplemental­
figure 1D,E and online supplemental table 3). IL23A expres-
sion was significantly upregulated under conditions of LPS or 
L18MDP stimulation and IL-10 signalling blockade (online 
supplemental figure 1C,D).
To investigate the regulation of secreted proteins by IL-10, 
we analysed cell culture supernatants after 16 hours of stimu-
lation (figure 1A). LPS stimulation significantly upregulated 
protein­secretion­in­17­among­the­40­proteins­tested­(fc≥4-­fold,­
BH- adjusted p<0.05). The addition of IL-10 blockade signifi-
cantly upregulated six of the LPS- induced factors (IL- 23p19, 
GM- CSF, IL-1α, IL- 12p70, IL- 12p40 and interferon (IFN)-γ) 
(BH-­adjusted­ p<0.05,­ fc≥4­fold)­ (figure 1A). Compared with 
control, LPS stimulation resulted in a mean 85.23- fold induc-
tion (mean concentration control: 3.30 pg/mL, mean concen-
tration LPS: 135.98 pg/mL) of IL-23 (BH- adjusted p<0.05), 
while combined LPS and anti- IL- 10R treatment induced a mean 
2544.95- fold increased (mean concentration LPS and anti- 
IL- 10R: 4737.57 pg/mL) IL-23 secretion (BH- adjusted p<0.05) 
(figure 1B). IL-23 mRNA and protein expression in PBMC were 
not correlated with disease subset or disease activity (online 
supplemental figure 2A‒D). Similarly, in previous studies, IL-23 
did not emerge as a biomarker of disease phenotype (CD/UC/
healthy controls) or disease activity in treatment- naïve or treated 
patients with IBD.17 22 23
We next sought to investigate IL-10 and IL-23 produc-
tion at the single- cell level and analysed monocytes cytokine 
production by flow cytometry. At 16 hours poststimulation, 
monocytes produced IL-10 but low IL- 12p40 and IL- 23p19. 
The synthesis of all three proteins was significantly increased 
when cells were stimulated with LPS and anti- IL- 10R. IL-23+ 
(IL- 12p40+IL- 23p19+) and IL-12+ (IL- 12p40+IL- 23p19–) cell 
frequencies and mean fold change were significantly greater 
in CD14+ relative to CD14– leucocytes after IL-10 receptor 
blockade (IL-23: CD14–: fc=2.7, CD14+:­ fc=28.5;­ IL-12:­
CD14–: fc=1.1, CD14+: fc=3.5) (figure 1D‒F). These results 
were confirmed in PBMC obtained from healthy donors (HDs) 
(IL-23: CD14–: fc=7.3, CD14+:­ fc=13.3;­ IL-12:­ CD14–: 
fc=1.9, CD14+: fc=6.3) (online supplemental figure 3A‒C). 
Together, these results demonstrate that IL-10 signalling 
Significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► We identify subgroups of patients with IBD that might 
benefit from IL- 23p19 and/or IL-1α/IL-1β-targeting therapies 
upstream of IL-23.
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Figure 1 IL-10 regulates IL23A transcription and IL-23 protein secretion in a subset of monocytes from patients with IBD. (A) Analysis of PBMC 
culture supernatants collected after 16 hours of stimulation with LPS±IL- 10R blocking antibodies expressed as log2 fold change to unstimulated 
PBMC (Ctrl) or LPS- stimulated PBMC (n=28; mean±SEM; Wilcoxon test, BH- adjusted p values). (B) IL-23 protein concentrations in culture 
supernatants expressed as fold change to unstimulated PBMC (n=28; mean±SEM; Friedman test with FDR- adjusted p values). (C) RT- qPCR analysis 
of relative IL23A expression in PBMC following 16 hours of stimulation (n=45; mean±SEM; Kruskal- Wallis test, BH- adjusted p values). (D) Contour 
plot presentation of IL- 23p19- producing, IL- 12p40- producing and IL-10- producing live leukocytes and CD14 surface expression measured at 16 hours 
poststimulation in PBMC. (E) Frequencies of IL- 12p40+IL- 23p19+, IL-10+ and IL- 12p40+IL- 23p19– CD14+ and CD14– cells in total live leukocytes 
(n=18, mean±SEM, Mann- Whitney test). (F) Frequencies of IL- 12p40+IL- 23p19+, IL-10+ and IL- 12p40+IL- 23p19– of CD14+ cells (n=18, mean±SEM, 
Mann- Whitney test). BH, Benjamini- Hochberg; Ctrl, control; EGF, epidermal growth factor; FDR, false discovery rate; G- CSF, granulocyte- colony 
stimulating factor; IL, interleukin; LPS, lipopolysaccharide; MDC, macrophage- derived chemokine (CCL22); n.s., not significant; PBMC, peripheral blood 
mononuclear cells; RANTES, regulated upon activation - normal T cell expressed and presumably secreted (CCL5); RT- qPCR, real- time quantitative PCR; 
TNF, tumour necrosis factor. *pvalue 0.05, **pvalue<0.01, ***pvalue<0.001, ****pvalue<0.0001.
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regulates IL-23 (IL- 12p40+IL- 23p19+) production in a subset 
of CD14+ monocytes (IBD mean=3.03%, 95% CI of the mean: 
lower=1.11,­ upper=4.96;­ HD­ mean=5.32%,­ 95%­CI­ of­ the­
mean: lower=3.51, upper=7.14).
Single-cell sequencing identifies inflammatory IL-10-
regulated monocyte phenotypes
FACS analysis suggested the presence of unknown functional 
heterogeneity within the population of stimulated CD14+ 
monocytes (see e.g. figure 1D). To characterise the LPS- induced 
and IL-10- regulated transcriptional profile of monocytes subsets, 
and to differentiate population- wide transcriptional changes 
from subset- specific responses we performed single- cell RNA 
sequencing (scRNA- Seq) of unstimulated, LPS- stimulated and 
LPS and anti- IL- 10R- treated CD14+ MACS- sorted monocytes 
from HDs (figure 2A). Flow cytometry analysis of the expression 
of CD14, CCR2 and CD16 by these cells prior to scRNA- Seq 
confirmed the presence of ‘classical’, ‘intermediate’ and ‘non- 
classical’ monocytes at the expected frequencies in each of the 
samples (online supplemental figure 4A–C). Among the eight 
clusters of monocytes that were detected, two clusters emerged 
after LPS stimulation and three additional clusters largely 
comprised of LPS and anti- IL- 10R stimulated cells (figure 2A,B).
The eight clusters showed discrete gene expression (figure 2C 
and online supplemental figure 5) and were enriched for biolog-
ical processes suggestive of different functional specialisations 
(online supplemental figure 6A). The majority of unstimulated 
monocytes were lysozyme+ (LYZ), CD52+ (CAMPATH1) and 
FCN1+ expressing CD14high monocytes (cluster 0—unstim-
ulated) typical of classical monocytes, while a minority of 
unstimulated monocytes displayed a CD52+, FCN1+, CD16+ 
(FCGR3A) CD14low phenotype (cluster 7—unstimulated) char-
acteristic of intermediate or non- classical monocytes in keeping 
with the flow cytometry data (online supplemental figure 4).24 
Two clusters of cells that emerged following LPS stimulation 
were composed of CD14+IL1B+cells. While these two clusters 
of cells had very similar profiles (online supplemental figure 6B), 
the first showed lower expression of CD163 and CD300E and 
was enriched for genes associated with ‘T- cell tolerance induc-
tion’ (cluster 1—LPS- stimulated), while the second displayed 
higher CD163 and CD300E expression and an enrichment 
for ‘monocyte activation’ genes (cluster 2—LPS- stimulated). 
The three additional monocyte phenotypes that appeared on 
combined LPS stimulation and IL- 10R blockade were demar-
cated by (1) high expression of type I IFN- responsive genes (eg, 
IFIs, IFITs, ISGs, OASs and IRFs) and genes linked to antigen 
processing and presentation (e.g. B2M, CCR7, HLA and CD74) 
(cluster 3—LPS and anti- IL- 10R, called IFN- induced mono-
cytes);­(2)­high­expression­of­ITGAX and enrichment for genes 
associated with ‘superoxide generation’ and ‘positive regulation 
of neutrophil activation’ (cluster 6—LPS and anti- IL- 10R, called 
microbicidal monocytes) and (3) expression of proinflammatory 
genes including (IL1B, IL6, IL23A, CCL20 and PTGS2) and 
enrichment of genes associated with ‘Th17 cell lineage commit-
ment’, ‘positive regulation of acute inflammatory response’ 
and ‘IFN-γ production’ (cluster 4—LPS and anti- IL- 10R, called 
IL-23+ inflammatory monocytes). These three phenotypes in 
LPS- stimulated anti- IL- 10R- treated monocytes were replicated 
in a second donor (online supplemental figure 6C).
More detailed examination of the expression of key cytokines and 
their receptors revealed that while IL23A and IL1R1 were detected 
in a cluster- specific manner under the ‘hyperinflammatory’ LPS 
and anti- IL- 10R condition, IL10, IL10RA and IL10RB, as well as 
IL1A/IL1B mRNA showed a broader, cross- condition expression 
(figure 2D). Finally, we sought to compare the monocyte phenotypes 
that we identified following ex vivo stimulation with those reported 
for colonic mononuclear phagocytes in human IBD. We show that 
many of the genes associated with inflammatory mononuclear 
phagocyte phenotypes in CD9 (‘inflammatory macrophages’) and 
UC25 (‘inflammatory monocytes’) were upregulated in clusters asso-
ciated with LPS or LPS+anti- IL- 10R stimulation (figure 2E). Clus-
ters mainly composed of cells from the LPS+anti- IL- 10R stimulation 
condition showed the highest induction of the cassettes of disease- 
associated cytokines and chemokines, with the IL23A+ cluster 4 
being marked by a particularly high expression of IL6, IL1A, IL1B, 
TNF and OSM, as well as elevated levels of IL10 (figure 2D).
IL-10-producing monocytes control IL-23-producing 
monocytes through paracrine signalling
In PBMC, we observed that IL23A and IL10 mRNA expression 
were strongly correlated (Spearmans’ r=0.84, p<0.0001) when 
stimulated with LPS and IL- 10R blockade (online supplemental 
figure 7A). These data indicate that IL10 mRNA expression itself 
is tightly regulated by IL-10 signalling as part of a negative feed-
back mechanism. We assumed that IL23A and IL10 would be 
produced by the same cells. However, inspection of the single- 
cell data suggested that this might not be the case. Intracellular 
flow cytometry demonstrated that IL-10 expression in mono-
cytes at the population level was earlier then the upregulation of 
IL-23 (online supplemental figure 7B) and that IL-10 and IL-23 
largely originate from distinct cells in both monocytes isolated 
from HD and patients with IBD (figure 3A,B). While all subsets 
of IL- 23p19 and/or IL-10- producing monocytes were deregu-
lated on IL- 10R blockade, monocytes isolated from patients with 
IBD showed decreased frequencies of IL-10+ single producing 
monocytes and IL- 23p19+IL-10+ coproducing monocytes but 
not IL- 23p19 single producing monocytes when compared with 
monocytes isolated from healthy donors (figure 3C). The pres-
ence of diverse cytokine profiles in monocytes indicated that 
IL-10 may regulate IL-23 production through a paracrine mech-
anism in functionally distinct cells. Alternatively, monocytes 
might express IL10 and IL23A mRNA sequentially (ie, with 
early IL-10 producer becoming IL-23 producers). Otherwise, the 
pattern of segregated IL-10 and IL-23 protein expression might 
result from oscillatory expression of IL10 and IL23A mRNA. 
To distinguish between these possibilities, we performed a dual- 
colour ELISpot assay using MACS- purified monocytes. This 
approach captured cytokine production in the individual cells 
over the full duration of their culture in vitro. In line with a para-
crine model where IL-10- producing monocytes regulate IL-23 
production in others, we found that IL-10- producing monocytes 
were distinct from IL-23- producing monocytes (figure 3D,E, and 
online supplemental figure 7C). These results suggest that the 
IL-10- producing monocytes regulated the IL-23- producing cells 
through a paracrine mechanism and that the observed mono-
cyte heterogeneity was not the result of sequential or oscillatory 
cytokine secretion. The absence of aggregates of either IL-10- 
secreting or IL-23- secreting monocytes additionally demon-
strated that the development of IL-23- producing monocytes did 
not result from local cell segregation in tissue culture.
Deconvolution of intestinal IL-23 gene expression in 
intestinal tissue
We next sought to understand the context of IL-23 expression 
during intestinal inflammation. We compared expression of 
IL-23 in ileal biopsies from 219 patients with CD and non- 
inflamed controls in samples from the Risk Stratification 
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Figure 2 Single- cell RNA sequencing identifies subsets of inflammatory monocytes. (A) The tSNE plot shows the subpopulations of unstimulated, 
LPS- stimulated and combined LPS and anti- IL- 10R- stimulated monocytes that were identified by a graph- based clustering approach following 
cross- condition alignment with Harmony (for details please see the online supplemetary materials and supplementary references61) (B) Bar plots 
show the number and frequency of cells in each of the identified clusters among three stimulation conditions in each of the identified clusters. (C) 
The violin plots show expression (x- axis) of genes characteristic of the identified monocyte clusters (y- axis). (D) Expression of IL10, IL10RA, IL10RB, 
IL23A, IL1B and IL1R1 across the single monocytes according to (A). (E) The dot plot shows the expression of genes associated with Mo and Mφ in 
single- cell studies of CD (Martin et al)9 and UC (Smille et al)25 in the identified clusters of single cells (A). The genes shown were previously identified 
as characteristic of inflammatory macrophages in CD (‘Martin et al infl. Mφ’) or in anti- TNF- resistant CD (‘GIMATS–infl. Mφ’),9 as characteristic of 
inflammatory monocytes (‘Smille et al infl. Mo’) or higher in monocytes from inflamed versus healthy tissue (‘Smille et al infl.>healthy’) in UC,25 as 
characteristic of resident intestinal Mφ in the context of CD (‘Martin et al.–res. Mφ’ and ‘GIMATS–res. Mφ’),9 or more highly expressed in healthy than 
diseased tissue in the context of UC (‘Smille et al healthy>infl.’).25 For further details, please see the Methods section. CD, Crohn’s disease; GIMATS, 
IgG plasma cells - inflammatory mononuclear phagocytes - activated T cells - stromal cells; IL, interleukin; LPS, lipopolysaccharide; Mφ, macrophages; 
Mo, monocyte; TNF, tumour necrosis factor; tSNE, t- distributed stochastic neighbour embedding.
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and Identification of Immunogenetic and Microbial Markers 
of Rapid Disease Progression in Children with Crohn’s 
Disease(RISK) study 26 (controls without ileal inflamma-
tion include 42 healthy donors and 61 patients with UC) 
(figure 4A). As expected, IL23A and IL12B were expressed 
in the CD patient samples, along with IL1A, IL1B and IL6. 
However, we also found IL23A and IL12B expression in 
non- inflamed control biopsies (figure 4A,B) where IL23A 
expression was associated with TNF rather than IL1B expres-
sion (figure 4C,D). We therefore performed weighted gene 
Figure 3 The monocyte response to PRR stimulation is heterogeneous, revealing a paracrine mechanism of IL-10- depedent regulation of IL-23 
production. (A) Representative contour plot presentation showing IL- 23p19+ and IL-10+ frequencies in monocytes derived from a healthy donor 
and a patient with IBD at 16 hours poststimulation. (B) IL- 23p19+IL-10–, IL- 23p19+IL-10+ and IL- 23p19–IL-10+ monocyte frequencies at 16 hours 
poststimulation (HD: n=26, IBD: n=18; mean±SEM; Friedman test with FDR- adjusted p values). (C) Monocyte cytokine frequencies according to 
(A) and (B), comparing patient subgroups and stimulation conditions (HD: n=26, IBD: n=18; mean±SEM, Mann- Whitney test). (D) Representative 
dual- colour ELISpot images showing non- stimulated, LPS- stimulated and combined LPS and anti- IL- 10R- stimulated monocyte IL-10 secretion (blue), 
IL- 12p40+IL- 23p19+ secretion (red) and combined production of both cytokines (violet/brown). Numbered magnifications of distinct spots detected 
in the LPS+anti- IL- 10R- stimulated condition are shown on the right. (E) Dual- colour ELISpot counts from three independent experiments (n=6, 
Mann- Whitney test). Ctrl, control; FDR, false discovery rate; IL, interleukin; n.s., not significant; LPS, lipopolysaccharide; SFU, spot forming units. 
*pvalue<0.05, **pvalue<0.01, ***pvalue<0.001, ****pvalue<0.0001.
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Figure 4 An IL-10- regulated inflammatory monocyte gene signature informs IL-23 and IL-1 targeting therapeutic approaches in IBD. (A) Patients 
of the RISK cohort (diagnosis and subtype as shown in top panels) were clustered according to the expression of 22 modules of coexpressed genes 
(see online supplemental figure 7A). The upper heatmap shows expression of key cytokines across the cohort. The lower panel shows expression of 
the eigengenes of two of the identified modules of coexpressed genes. (B) The expression of IL10, IL12B and IL23A within the different patient strata 
of the RISK cohort. (C,D) Correlation of IL23A with IL1B (C) and IL23A with TNF (D) in the inflamed (red) and non- inflamed (blue) CD patient biopsies 
of the RISK cohort. (E) Correlation of genes specific to LPS and anti- IL- 10R- stimulated monocytes with the ‘inflammatory cytokine’ and ‘lymphocyte 
differentiation’ gene modules in the RISK cohort data identifies three subsets (shaded (i) black, (II) grey and (III) green boxes). (F) Assessment of 
the ability of the identified monocyte genes to predict anti- TNF non- response (x- axis, GSE12251) and diagnosis of Crohn’s (y- axis, RISK cohort). The 
dashed lines indicate random classifier performance. (G,H) Comparison of the ability of the identified subsets of monocyte genes to predict TNF non- 
response (GSE12251) and diagnosis of CD in the RISK cohort (Wilcoxon tests, colours as shown in panels E,F). AUPRC, area under precision recall 
curve; CD, Crohn’s disease; IL, interleukin; LPS, lipopolysaccharide; n.s., not significant; RISK, Risk Stratification and Identification of Immunogenetic 
and Microbial Markers of Rapid Disease Progression in Children with Crohn’s Disease study; TNF, tumour necrosis factor; WGCNA, weighted gene 
correlation network analysis. *pvalue<0.05, **pvalue<0.01, ***pvalue<0.001, ****pvalue<0.0001.
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correlation network analysis27 to investigate the possible 
sources and roles of IL23A in the inflamed and non- inflamed 
intestines (online supplemental figure 8A). This analysis iden-
tified 22 modules of coexpressed genes that were named 
according to their gene members and enrichments for biolog-
ical pathways and sets of cell- type marker genes (online 
supplemental table 4). Clustering of the modules by their 
expression patterns in the RISK cohort patients identified 
six major groups that could be broadly distinguished by their 
correlations with diagnosis of CD, IL23A expression, epithe-
lial gene expression, mitochondrial activity and cell growth 
genes (online supplemental figure 8A,B).
Most prominently, we found an ‘inflammatory cytokine’ 
module that was significantly correlated with both CD (r=0.55) 
and IL23A expression (r=0.35) (online supplemental figure 8B). 
This module contained key myeloid and stromal markers genes 
(CD14 and PDPN), proinflammatory cytokines (including OSM, 
IL1B and IL6) and fibroblast activation protein (online supple-
mental figure 8B) in keeping with the emerging concept of a 
pathogenic myeloid- stromal cell circuit in IBD.18 24 Intriguingly, 
however, we found that IL23A expression was most strongly 
correlated with two modules of ‘immune cell differentiation’ 
(r=0.7) and ‘lymphocyte differentiation’ (r=0.71) genes (online 
supplemental figure 8A). Of these, the immune cell differenti-
ation module was weakly correlated with CD (r=0.2), associ-
ated with expression of myeloid (CD14) and lymphoid (CD79A, 
CD4) cell markers, and enriched for ‘myeloid DC differenti-
ation’ (online supplemental figures 8B and 9A). The lympho-
cyte differentiation module showed an expression signature 
suggestive of lymphoid follicles, including individual markers 
of B- cell and T- cell identity (CD79A and CD4) and differenti-
ation (BACH2)25 26 (online supplemental figure 8B), as well as 
enrichments for gene ontology categories related to lymphoid 
cell differentiation, proliferation and selection (online supple-
mental figure 9A). While the lymphocyte differentiation module 
was not correlated with CD, it was unique in showing signif-
icant enrichments for two sets of IBD Genome- wide associa-
tion study (GWAS)- associated genes (OR>3), suggesting that 
this set of genes is relevant for the pathogenesis of IBD (online 
supplemental figure 9B). We also noted that both of the IL23A- 
associated immune cell differentiation and lymphocyte differen-
tiation modules were significantly enriched for genes belonging 
to the KEGG ‘Th17 cell differentiation’ pathway (online supple-
mental figure 9A).
Overall, the network analysis suggested that IL-23 expres-
sion was primarily associated with lymphoid cell differentiation 
in both health and disease. We therefore sought to understand 
which of the IL-10- regulated monocyte genes were specific to 
disease- associated inflammation. We correlated the expres-
sion of a curated set of IL-10- regulated monocyte genes (35 
genes specific to combined LPS and anti- IL- 10R stimulation 
scRNA-­Seq;­figure 4E,F;­online­supplemental­methods­section,­
‘Identification and characterisation of an IL-10- responsive 
monocyte gene signature’) with the eigengenes for the CD- as-
sociated inflammatory cytokine and the non- inflammatory 
lymphocyte differentiation modules in the RISK cohort data. 
This analysis identified three subsets of IL-10- regulated mono-
cyte genes (figure 4E). These comprised (1) genes correlated 
only with the CD associated inflammatory cytokine module 
(black box, figure 4E);­(2)­a­set­of­genes­correlated­with­both­the­
inflammatory cytokine and lymphocyte differentiation modules 
(grey box, figure 4E);­ and­ (3)­ genes­ correlated­with­ only­ the­
non- inflammatory lymphocyte differentiation module (green 
box, figure 4E). The IL-10- regulated genes that correlated with 
the inflammatory cytokine but not the lymphocyte differenti-
ation eigengene (black box, figure 4E) showed a significantly 
superior ability to predict anti- TNF response after 4–6 weeks of 
treatment in an independent cohort of patients with UC (UC- co-
hort GSE12251)28 and diagnosis of CD in the RISK cohort26 
(figure 4F‒H, online supplemental table 5). By contrast, IL-10- 
regulated monocyte genes that correlated with lymphocyte 
differentiation, but not inflammatory cytokines, had poorer 
predictive ability (figure 4F‒H). To validate our findings, we 
analysed intestinal transcriptome data of an additional adult 
cohort of patients with CD and UC (GSE16879).28 Similar to 
our initial results, inflammatory monocytes gene expression 
predicted disease activity and anti- TNF non- response in adult 
patients with CD ileal biopsy transcriptomes. In colonic biop-
sies, these genes were not predictive of disease activity but distin-
guished patients with CD or UC anti- TNF non- response (online 
supplemental figure 10A,B).
These data therefore identify a subset of IL-10- regulated 
monocyte- derived genes, including CXCL1/2, IL1A, IL1B, INHA, 
IL6, CCL3/4, PTGS2, CSF2/3 and GBP1, which show a specific 
association for disease- associated intestinal inflammation in the 
RISK and GSE16879 CD cohorts. By contrast, cytokines such 
as IL-23 and TNF were not specific for disease suggestive of 
context- dependent roles in homeostasis and inflammation.
Monocyte exposure to whole bacteria causes aquired IL-10 
resistance and IL-23 secretion
The analysis of gene expression data in the RISK cohort suggests 
IL-23 expression despite the presence of IL-10 in a subset of 
patients with macroscopic inflammation and deep ulcerating 
IBD in the absence of Mendelian IL-10 or IL- 10R loss of func-
tion DNA variants, that is, functional IL-10 resistance. In light 
of the epithelial barrier defect in ulcerating disease that predis-
poses to bacterial translocation, we tested whether exposure of 
monocytes to bacteria can induce functional IL-10 resistance. 
We treated monocytes for 16 hours with heat killed Salmo-
nella typhimurium or Escherichia coli strain Nissle. Interest-
ingly, monocytes produced IL-23 and IL-10 on stimulation 
(figure 5A,B) reminiscent of LPS stimulation in presence of 
IL- 10R blockade. The cellular dichotomy of IL-23 and IL-10 
production was maintained under these conditions (figure 5B). 
To assess IL-10 responsiveness in previously stimulated mono-
cytes, we extensively washed cell cultures, subsequently exposed 
those to recombinant human IL-10 and evaluated phosphoryla-
tion of signal transducer and activator of transcription (STAT)3 
(figure 5C). Indeed, bacterial stimulation was associated with 
an increased proportion of IL-10 non- responsive cells, demon-
strating that monocyte exposure to whole bacteria induced a 
state of acquired IL-10 resistance (figure 5D,E). Importantly, 
the reduced phosphorylation of STAT3 in monocytes that were 
exposed to whole heat killed bacteria was not due to increased 
cell death under these culture conditions (online supplemental 
figure 11A,B).
IL-1α and IL-1β are essential for monocyte IL-23 production
The regulation of monocyte- derived IL-23 and IL-10 suggested 
coregulation via additional factors (likely cytokines). We there-
fore investigated the functional effects of 11 coregulated cyto-
kines on monocyte IL-23 production (figure 6A,B and online 
supplemental figure 12A,B). Strikingly, when blocking IL- 1R1, 
IL-23 production was near completely abolished (figure 6A,B 
and online supplemental figure 12A‒C). Blocking IL-1β or 
IL-1α alone had only partial or no effect on IL-23 production, 
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indicating that either cytokine can compensate for the absence 
of the other in driving monocyte IL-23 production (figure 6A 
and online supplemental figure 12A). The effect of IL-1β on 
IL-23 expression was context specific, since addition of IL-1β 
in the presence of anti- IL- 10R blockade alone did not induce 
IL-23 expression (online supplemental figure 12D). None of the 
other tested cytokines (GM- CSF, IL-6, IL-11, IL- 17A, IL-18, 
IL-19, IL-23, IL-24, IL-36γ, TNF and type I IFN) demonstrated 
a significant impact on IL-23 production. Although not essen-
tial, addition of IFN-γ or IL-12 significantly increased monocyte 
IL-23 production (figure 6A,B and online supplemental figure 
12A,B). To investigate the effects of IL- 1R1 blockade on func-
tional monocyte clusters, we stimulated PBMC from HDs with 
combinations of LPS and anti- IL- 10R and analysed monocyte 
metaclusters- associated protein expression. In line with the 
single- cell mRNA sequencing experiments, the predicted clusters 
associated with LPS and combined LPS and anti- IL- 10R stimu-
lation (figure 6C). Blockade of IL- 1R1 specifically inhibited the 
development of IL-23- producing monocytes, while other mono-
cyte clusters remained largely unaffected (figure 6C,D). Impor-
tantly, monocyte IL-23 production induced by whole bacteria 
exposure was similarly dependent on IL- 1R1 signalling (online 
supplemental figure 13A,B), suggesting that IL-23 is downstream 
of IL-1 signalling also in the context of bacteria- induced acquired 
IL-10 signalling defects.
We next used a mathematical model of ordinary differential 
equations as an objective analysis tool to investigate the rela-
tive direct and indirect impacts of the addition or blockade of 
various cytokines or blockade of cytokine receptors (figure 6E). 
The model tests whether cytokine production is modulated 
by other key cytokines that are produced by monocytes (TNF, 
IL-1α, IL-1β,­ IL-6,­ IL-10­ and­ IL-23;­ false­ discovery­ rate­
(FDR)- corrected paired Wilcoxon test). Modelling all feasible 
network configurations led to the conclusion that most of the 
n=231-1 configurations could be excluded a priori. We identi-
fied an optimal network describing the core network dynamics 
by ranking the models based on their fit to the data using the 
Akaike information criterion (figure 6F). This model supported 
IL-10 signalling as negative feedback mechanism and IL-1β as a 
positive regulator of IL-23 production, with IFN-γ acting as an 
amplifier. In addition, the model predicted the positive effect 
of IL-1β on IL-23 production to be independent of regulating 
IL-1α, IL-6, IL-10 or TNF and the negative regulation of IL-23 
by IL-10 to be independent of the effect of IL-10 on the other 
cytokines present in the model (IL-1α, IL-1β, IL-6 and TNF). 
Interestingly, the model suggests that IFN-γ might amplify 
IL-1α through the suppression of IL-10, but amplify IL-23 inde-
pendently of its inhibitory effect on IL-10 (the upregulatory 
edge from IFN-γ to IL-1α present in figure 6E was removed in 
the final model since this can be accounted for by a decrease in 
Figure 5 Monocyte stimulation with whole bacteria causes IL-10 resistance and IL-23 secretion. (A) Frequencies of IL- 12p40+IL- 23p19+ in live 
CD14+ at 16 hours following stimulation (n=8; mean±SEM, Mann- Whitney test). (B) Dot plots showing IL- 12p40, IL- 23p19 and IL-10 in live CD14+ 
monocytes from a healthy donor. (C) Scheme for the assessment of monocyte IL-10 responsiveness. (D) Frequencies of phospho- STAT3– live monocytes 
without cytokine stimulation (control) and following 15 min IL-10 (50 ng/µL) stimulation (n=8; mean±SEM, Mann- Whitney test). (E) Representative 
histograms showing phosphorylation of STAT3 in non- treated (control) or IL-10- treated (+IL-10) live monocytes. Percentages of IL-10 stimulation- 
resistant monocytes are indicated. IL, interleukin; LPS, lipopolysaccharide. *pvalue<0.05, **pvalue<0.01, ***pvalue<0.001, ****pvalue<0.0001.
10 Aschenbrenner D, et al. Gut 2020;0:1–14. doi:10.1136/gutjnl-2020-321731
Inflammatory bowel disease
Figure 6 IL-1α and IL-1β signalling are essential for monocyte IL-23 production. PBMC from healthy donors (n>4) were stimulated for 16 hours 
with combinations of LPS and aIL- 10R in the presence of indicated exogenous human recombinant cytokine (all 10 ng/mL) and/or cytokine/cytokine 
receptor blockade (all antibodies 10 µg/mL). (A) Frequencies of IL- 12p40+IL- 23p19+ live CD14+ monocytes (Wilcoxon test, 95% CI). (B) Representative 
dot plot showing intracellular IL- 12p40 and IL- 23p19 according to (A). (C) tSNE presentation of IL- 23p19, CCL20, HLA- DR, IDO-1, CCL2, S100A8, RPS6 
and SPINK-1 expression in live CD14+CD3–CD19–CD56–- gated monocytes. Analyses of three healthy donors are shown as overlay. (D) Frequencies 
of monocyte clusters across stimulations based on cluster- specifying protein expression (n=6; one- way analysis of variance after BH correction). (E) 
The extensive model represents the effects of the addition or blockade of cytokines in a PBMC culture in the presence of LPS or LPS and anti- IL- 10R. 
Differences of cytokine addition or blockade in LPS- stimulated samples (dashed arrows), in LPS and anti- IL- 10R- stimulated samples (solid arrows) and 
in LPS and anti- IL- 10R- stimulated and anti- IL-1β treated conditions (dotted arrows). Nominal effects with p>0.05 after false discovery rate correction 
(BH) are shown in parentheses. (F) A reduced complexity model was established by focusing on informative cytokine interactions. Edge weights 
are defined as the relative contribution to model fit and are dependent on the network configuration considered. The edges of the 20- edge model 
have been coloured based on their weight. BH, Benjamini- Hochberg; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; PBMC, peripheral blood 
mononuclear cells; TNF, tumour necrosis factor.
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IL-10;­figure 6F). Finally, negative regulation of IL-23 by IL-10 
is predicted to be independent of the effect of IL-10 on the other 
modelled cytokines.
IL-1 regulates IL-23 production in genetic IL-10 signalling 
defects
To confirm these predictions, we investigated the effect of 
IL- 1R1 blockade on IL-23 expression in the context of genetic 
deficiency of IL-10 signalling. We stimulated PBMC obtained 
from patients with infantile- onset IBD due to an IL10RA or 
IL10RB gene defect. Interestingly, patient- derived monocytes 
produced IL-23 in response to LPS stimulation alone, indicating 
the intrinsic defect in IL- 10R- dependent regulation, confirmed 
by the inability of exogenous IL-10 to suppress monocyte IL-1β 
production. Strikingly, IL- 1R1 blockade inhibited monocyte 
IL-23 production in LPS- stimulated PBMC from IL- 10R defi-
cient patients (figure 7A,B). Together, these analyses confirmed 
IL-10 as the major negative regulator of IL-23 production, while 
IL-1 signalling (and in particular IL-1β) is essential for monocyte 
IL-23 synthesis.
DISCUSSION
We identify key regulatory circuits of IL-23 production by inflam-
matory monocytes. These include failure of paracrine IL-10- 
mediated control, as well as autocrine and paracrine signalling 
of IL-1α and IL-1β in response to inflammatory stimuli. Indeed, 
increased IL-23 production can be observed in monocytes from 
patients with infantile- onset Mendelian IL-10 signalling deficiency 
or experimental blockade of the IL-10 receptor. In addition, we 
newly show that monocytes that respond to whole bacteria express 
IL-23 as a consequence of acquired IL-10 non- responsiveness. 
Most importantly, we define a transcriptional signature of IL23A+ 
inflammatory monocytes that indicates a state of acquired IL-10 
non- responsiveness in a subgroup of patients with deep ulcers and 
compromised epithelial function where monocytes may directly 
respond to whole bacteria. This signature predicts both diagnosis 
of CD and resistance to anti- TNF treatment similar to previously 
described OSM expression.18 Although derived from analysis of 
ileal inflammation in CD, this signature was also able to predict 
anti- TNF failure from the transcriptional profiles of colonic 
samples in UC, suggesting a common role for hyperinflammatory 
monocytes in treatment- resistant disease in both IBD subtypes. 
Interestingly, loss of IL-10 responsiveness induces IL23A mRNA 
and IL-23 protein expression only in a small fraction of monocytes 
that express the IL-1 receptor IL1R1. This selective IL-23 expres-
sion contrasted with pervasive induction of IL-1α and IL-1β 
expression, as well as a broad induction of IL-10 expression in 
monocytes under the same hyperinflammatory condition.
Our data support context- specific roles of IL-23 in driving 
the differentiation of pathogenic Th17/Th1 cells in the presence 
of IL-129 that are enriched in inflamed intestinal tissue from 
patients with IBD30 31 while supporting the development of non- 
pathogenic Th17 cells under homeostatic conditions such as 
those found in mucosa- associated lymphoid tissue (MALT) - in 
healthy individuals.
Together, these results suggest that subgroups of patients 
with active disease may benefit from anti- IL- 23p19 therapy 
and that the targeting of upstream cytokines that regulate IL-23 
expression in inflammation, such as IL-1 might provide a selec-
tive means to block pathogenic IL-23 expression. The critical 
element that differentiates homeostatic IL-23 and TNF expres-
sion from hyperinflammation is the coexpression of a multi-
tude of IL-10- regulated factors, including IL-1α and IL-1β in 
patients with severe active disease and anti- TNF treatment 
non- responsiveness.
The strong predictive ability of an IL-10- sensitive inflamma-
tory monocyte signature (CD14, IL1A, IL1B, OSM, PTGS2, 
IL6, CCL2/3 and CXCL1/2) emphasises a surprising and under-
estimated extent of IL-10 non- responsiveness in IBD. In those 
patients, inflammation is present despite transcription of IL-10 
(patients express a large amount of IL-10) and absence of patho-
genic variants within the IL-10 receptor (exome sequencing 
did not reveal Mendelian forms of IL-10 receptor signalling 
defects in this cohort).32 The high expression of PTGS2 in this 
subgroup of patients with IBD represents an additional indi-
cator for deregulated IL-10 responses and intestinal antimicro-
bial immunity.33 Our experiments suggest that direct contact of 
monocytes with whole bacteria can induce IL-10 resistance that 
allows coexpression of IL-23 and IL-1 explaining the signature 
of IL-10 non- responsiveness in a subgroup of patients with intes-
tinal ulceration. IgG receptor IIa signalling in myeloid cells in 
response to immunoglobulin coated microbes may additionally 
amplify inflammasome- dependent induction of IL-1 synthesis.34 
An additional mechanism of reduced IL-10 responsiveness may 
be differential expression of IL- 10R1.35 36 Our ELISpot exper-
iments exclude differential spatial clustering of IL-10- secreting 
or IL-23- secreting monocytes, as well as oscillatory or sequential 
IL-10 and IL-23 transcription.
Figure 7 Monocyte IL-23 responses in patients with loss of function in IL- 10R1 and IL- 10R2. (A) Frequencies of IL- 12p40+IL- 23p19+ and IL-1β+ 
monocytes in PBMC from healthy donors and two patients with IL- 10R variants (IL10RA (p.R117H) and IL10RB (p.Y167C)) following 16 hours 
of stimulation with combinations of LPS (200 ng/mL), IL-10 (10 ng/mL), anti- IL- 10R (10 µg/mL), anti- IL- 1R1(10 µg/mL) and IFN-γ (10 ng/mL). IFN, 
interferon; IL, interleukin; LPS, lipopolysaccharide; PBMC, peripheral blood mononuclear cells.
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This suggests that the inflammatory microenvironment drives 
in parallel several monocyte effector programmes and monocyte 
to macrophage and DC differentiation processes, reminiscent 
of plasmacytoid DC stimulation with a single stimulus (R848 
or CpG) that induces diverse transcriptional states and cellular 
functions.37 This is likely a biological mechanism to ensure func-
tional heterogeneity under hyperinflammatory conditions, when 
diversity in the host defence towards a range of potential patho-
gens is essential.
Single- cell RNA transcriptomic approaches identified tran-
scriptional signatures in circulating and tissue human monocytes 
and macrophages,9 25 38–42 demonstrating phenotypical and func-
tional diversity in monocyte, macrophage and DC populations. 
We have focused on the cellular heterogeneity and inflamma-
tory response of peripheral monocytes because those cells are 
recruited into the gut and differentiate into proinflammatory 
major histocompatibility complex (MHC)- II- high monocytes 
and macrophages that outnumber resident, yolk sac- derived 
tissue macrophages during inflammation.43–45 Such proinflam-
matory macrophages have been characterised following in vitro 
differentiation using LPS stimulation and express IL-12 and 
IL-23 in response to STAT1- dependent IFN-γ signalling.46
Recently IL1Β+ ‘inflammatory monocyte’25 and IL1B+IL23A+ 
‘inflammatory macrophage’9 populations associated with 
inflammation and resistance to anti- TNF treatment have been 
described in single- cell studies of tissue from patients with UC25 
and CD.9 We found that, following stimulation with LPS in the 
presence of anti- IL- 10R blockade, a fraction of blood mono-
cytes acquired a IL1B+IL23A+ transcriptional signature that 
is very similar to those described for mononuclear phagocytes 
isolated from the inflamed intestinal biopsies of patients with 
CD and UC. This observation demonstrates the relevance of 
functional studies of peripheral monocytes for understanding 
the behaviour of these cells following their recruitment into the 
inflamed intestinal mucosa. Together with the previous find-
ings, our observations suggest that inflammatory monocytes 
and CX3CR1+IL-1β+ macrophages47 48 are likely to be major 
sources of IL-23 in the context of inflammasome activation and 
IL-1 production in the inflamed intestine and support a crit-
ical role for IL-1 in intestinal anti- TNF- treatment refractory 
inflammation.
Importantly, several cell types including regulatory T cells, B 
cells, macrophages and DCs produce IL-1049 and may therefore 
contribute to the negative regulation of proinflammatory IL-23- 
producing monocytes in tissue in vivo. While we have unrav-
elled the regulation of peripheral blood monocytes in IL-23 
responses ex vivo and related those to processes of inflammation 
in intestinal tissue from patients with IBD, in the tissue context 
complex and niche- specific cellular communication networks 
are expected to further modulate the regulation of monocyte 
inflammatory effector functions and IL-23 expression.
In individuals without intestinal inflammation, our network 
analysis suggested that IL23A expression was likely derived 
from terminal ileal MALT because the lymphocyte differentia-
tion to which it was assigned also showed strong correlations 
with orthologues of genes associated with murine small intestine 
lymphoid tissue (SILT), including IL22RA2, ITGAX27 as well as 
with VCAM1, which is a marker of lymphoid- associated villi in 
humans (online supplemental figure 5B). In such MALT tissue, 
which is hyperplastic in paediatric patients,50 the source of 
IL23A is most likely DCs, tolerogenic CD103+DC51 or macro-
phages as is known to be the case in mouse SILT.47 This work 
demonstrates the utility of network- based approaches for decon-
volving variance in gene expression that arises from the analysis 
of biopsy samples from tissues with complex microanatomical 
heterogeneity such as the small intestine.
Our mathematical model pinpoints IL-1 as a key positive regu-
lator of IL-23 expression in monocytes. Studies in monogenic 
forms of IBD suggest that IL- 1R1 blockade can resolve intestinal 
inflammation in patients with IL-10 receptor defects,52 meva-
lonate kinase defects and potentially gain- of- function NLRC453 
defects, which are all characterised by increased inflammasome 
activation and IL-1 secretion. It is therefore an attractive 
hypothesis that the hyperinflammatory IL1+PTGS+IL6+ signa-
ture might define an anti- IL- 1R1 responsive group of patients 
with IBD. Interventional studies are required to identify differ-
ential effects between IL-23 and IL-1 blockade since both have 
complex effects on licensing for effector cytokine production 
and differentiation of Th1 and Th17 cells.54 Altogether, our find-
ings may inform transcriptional diagnostic efforts to guide use of 
IL- 23p19 targeting therapies and suggest a role for therapeu-
tics capable of selectively blocking IL-23 in disease by targeting 
context- specific upstream factors such as IL-1.
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